

4TH ANNUAL NEWSLETTER



An Academic Research Summit Focusing on the Advancement
of EGFRm Treatment Paradigms through Meaningful Collaboration
between Physician Scientist Investigators and Patients



Follow us on Twitter: [@EGFRSUMMIT](https://twitter.com/EGFRSUMMIT)



Presented by the EGFR Resisters and Creative Educational Concepts, LLC.

Supported by an independent educational grant from AstraZeneca.



EGFR RESISTERS RESEARCH SUMMIT RECAP



The fourth annual EGFR Resisters Research Summit convened on November 17–18, 2022, at the Pendry in Chicago, Illinois, in person for the first time since the inaugural Research Summit in 2019. To celebrate this occasion, a number of alumni from the previous three years were invited back to provide updates to the research they presented in their respective year of participation and to share wisdom gained in the interim. The nine new young investigators (YIs), nine returning alumni, five Expert Judge Mentors, and three patient advocates—two in-person and one virtual—kicked off Thursday’s sessions with Introductory Remarks, Ice Breakers, and the first Small-group Table Discussions, where the new YIs were able to meet and greet both the returning alumni and the Expert Judge Mentors. Jill Feldman, co-founder of the EGFR Resisters, greeted the attendees with a Message from the EGFR Resisters, providing a foundation in why this type of research forum is essential not only for the researchers, but for the patient as well. Jill discussed the mission of the EGFR Resisters patient group and the critical need for research advancements in EGFRm non–small-cell lung cancer (NSCLC), the history of the EGFR Resisters Research Summit, and recent breakthroughs and significant obstacles affecting the care of their fellow survivors. The first day ended with a welcome reception and dinner, where all attendees were able to foster new and existing relationships.

Friday held two Young Investigator Research Presentation sessions and two Returning Alumni Research Updates sessions; the YIs presented their research to the Expert Judge Mentors, patients, and fellow YIs; the returning alumni provided updates in how their presented research has evolved since their time at the EGFR Resisters Research Summit. Mentoring Moments were shared with the YIs by Jill Feldman, providing context in how incorporating patients and patient advocates within clinical trial design is crucial, and by returning alumni Dr. Josh Sabari and Dr. Christine Bestvina, providing sage advice in navigating the transition from fellow to faculty and how best to protect their time as they enter early parenthood and develop their career as scientists.



One of the best conferences I’ve ever attended. It will have a long-lasting impact on my career due to the mentorship that we received as well as the friendships/collaborations that we created.





EGFR RESISTERS RESEARCH SUMMIT RECAP

As the first in-person EGFR Resisters Research Summit since 2019, the 2022 Research Summit provided a unique opportunity for multi-level mentorship where the returning alumni acted as peer-mentors. Peer-mentorship opportunities throughout the Research Summit and social gatherings exposed new YIs to the wisdom of returning alumni who have recently taken the “next steps” in their professional lives.

The EGFR Resisters Research Summit concluded with an awards ceremony and dinner on the heels of a collegial day and a half. To further instill the collegial nature of the EGFR Resisters Research Summit, returning alumni and Expert Judge Mentors were provided with awards of appreciation for their continuous commitment in advancing research alongside patient advocates. At the end of the awards ceremony, three participants were awarded for their exemplary work—the EGFR Resisters Distinguished Young Investigator, Runner-up, and Notable Alumni.

As part of the Annual EGFR Resisters Research Summit tradition, Jill Feldman, Ivy Elkins, and Dr. Stephen Liu participated in a recap video to provide members of the EGFR Resisters a highlight of the exciting work within EGFR-positive NSCLC. [Click here](#) to view the video.



I’m starting to build a network of like-minded colleagues...Participation in the summit also provided me with more confidence to pursue an academic path.



ABOUT THE EGFR RESISTERS PATIENT ADVOCACY GROUP

Established in 2017 by seven original members—who drew on their experience as patients, survivors, caregivers, and healthcare providers—the EGFR Resisters represent a grassroots, patient-driven community dedicated exclusively to changing EGFR-mutated lung cancer into a chronic, manageable disease. With more than 4,400 members from more than 97 countries across the globe, the EGFR Resisters have become a well-established and widely-known oncogene driver group that is galvanizing research efforts in meaningful and unique ways, including data gathering efforts such as Project PRIORITY and the EGFR Resisters Research Summit, which is a Young Investigator Forum that brings together established experts with the next generation of lung cancer researchers. CEC Oncology is excited and honored to partner with the EGFR Resisters in organizing and delivering the Research Summit each year.





Grand Prize



Paul Stockhammer, MD, PhD

*Resident Physician
Yale School of Medicine
New Haven, Connecticut*

Co-occurring Alterations in Multiple Tumor Suppressor Genes Associate with Outcomes in Patients with EGFR-mutant Lung Cancer

Dr. Stockhammer is a third-year internal medicine resident at the Yale School of Medicine. He obtained his MD/PhD from the Medical University of Vienna, Austria, where he studied the role of transforming growth factor- β in pleural mesothelioma and HDAC inhibitors in lung cancer. His current research in the Politi Lab at the Yale School of Medicine focuses on EGFR-driven lung cancer and drug resistance, investigating the relationship between EGFR and co-occurring tumor suppressor gene alterations. Following his internal medicine residency, Dr. Stockhammer intends to continue his training in a hematology/oncology fellowship, with sub-specialization in thoracic oncology. His overall career goal is to continue his academic career as a physician scientist.

“My current research at the Yale School of Medicine focuses on EGFR-driven lung cancer and drug resistance. Therefore, participating in the EGFR RRS and presenting my research builds logically on my current work and is a major next step forward in my early professional development as a thoracic oncology physician scientist. The opportunity to gather with peers, expert mentors, and patient advocates at the EGFR RRS to discuss our research projects with the common goal to help advance the field of EGFR-driven lung cancer and improve patient outcomes is of enormous value at my early stage of professional development and will shape me both as a researcher and as a physician.”

“I am planning to use the grant award for genomic analyses of EGFR-driven tumors, which will include genomic sequencing and storage of genomic data, to further investigate the association between concurrent genetic alterations and biological and clinical disease heterogeneity in EGFR-driven lung cancer. I am also planning to use the grant award for travel expenses to present my EGFR-related research at national and international conferences.”





Runner Up



Chetan Vakkalagadda, MD

*Hematology/Oncology Fellow
Northwestern University
Chicago, Illinois*

A Randomized Phase II Clinical Trial of Osimertinib with or without Olaparib in Patients with Stage IV EGFR-mutant NSCLC and Germline Mutations in the Homologous Recombination Repair Pathway: Trial in Progress

“There are several ways participation in the EGFR RRS has already impacted my professional development. I plan a career as a clinician investigator; being involved with groups such as EGFR Resisters will allow me to keep track with ongoing research in this field. Through the EGFR RRS, I have had the opportunity to build my network of colleagues interested in tackling major problems in thoracic oncology and doing so can allow further interdisciplinary and multicenter work. Having the opportunity to connect with patient advocates face-to-face as in the EGFR RRS will also ensure that my work moving forward is patient-centric. For these reasons, participating in the EGFR RRS will be very helpful in my career.”

“I plan to use my grant award for administrative and registration fees related to my research and to start translational work related to our clinical trial. With this being a clinical trial, we anticipate some administrative costs as we work to move this study through the scientific review process. I also plan to use a portion for travel and conference registration related to my clinical trial over the next year if this is to arise.”

Notable Alumni Award

In celebrating the accomplishments of the returning alumni within the field of EGFR-positive NSCLC research, the panel of Expert Judge Mentors recognized one standout alumni with the Notable Alumni Award. This award celebrates the impact of their efforts within the NSCLC research community and the example they set for both early career investigators and known thought leaders alike.



Joshua Sabari, MD

*Assistant Professor of Medicine
NYU Langone Health Perlmutter Cancer Center
New York, New York*

“Participating in EGFR RRS has been an amazing opportunity to collaborate with colleagues and develop the next generation of therapies that will help our patients with EGFR-mutant NSCLC.”

“I will use this award to further study resistance mechanisms in patients with EGFR-mutant NSCLC and to assist with costs in handling patient materials.”





Zofia Piotrowska, MD, MHS

*Activity Chair
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts*



Jessica Donington, MD, MSCR

*Planning Committee
Professor of Surgery
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, Illinois*



Mary Jo Fidler, MD

*Associate Professor of Medicine
Section Chief of Medical Oncology
Division of Hematology, Oncology, and Cell Therapy
Rush University Medical Center
Chicago, Illinois*



Stephen V. Liu, MD

*Thoracic Medical Oncologist
Associate Professor of Medicine
Georgetown University
Director of Thoracic Oncology
Head of Developmental Therapeutics
Georgetown University Hospital, Lombardi Comprehensive Cancer Center
Washington, DC*



Lecia V. Sequist, MD, MPH

*Landry Family Professor of Medicine
Harvard Medical School
Director of Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts*



All of the Expert Judge Mentors were fantastic!



Incredible group that provided critical yet appropriate feedback.



2022 EGFR RESISTERS RESEARCH SUMMIT PATIENT ADVOCATES



Ivy Elkins, MBA

Founding Member, EGFR Resisters
EGFR+ NSCLC since 2013
Evanston, Illinois



Jill Feldman, MA

Founding Member, EGFR Resisters
EGFR+ NSCLC since 2009
Deerfield, Illinois



Lindi Campbell

Founder, Breath of Hope Kentucky
EGFR+ NSCLC since 2020
Lexington, Kentucky



Jill, Lindi, and Ivy. I wish we could have more one-on-one sessions with advocates and mentors.



New Young Investigators



Rama Ali, PhD
Research Fellow
Vanderbilt University Medical Center
Nashville, Tennessee

EGFR Inhibition Induces Aberrant Cell Cycle Control, DNA Damage, and Apoptosis



Bailey Gleason Fitzgerald, MD
Hematology/Oncology Fellow
Tisch Cancer Institute, Mount Sinai
New York, New York

Predictors of Primary Osimertinib Resistance



Monica Chen, MD
Medical Oncology/Hematology Fellow
Memorial Sloan Kettering Cancer Center
New York, New York

A Phase 2 Single-arm Study of Amivantamab and Lazertinib in Metastatic EGFR-mutant Lung Cancer with Progressive or New CNS Metastases on Previous Treatment



Jennifer A. Marks, MD
Fellow Physician
Georgetown University
Washington, DC

Synchronous EGFR Mutations in Li Fraumeni Syndrome: A Clinical Dilemma



Mostafa Elbahrawy, MBBCh, MD, PhD
Research Fellow
Albert Einstein College of Medicine
The Bronx, New York

A Novel Therapeutic Monoclonal Antibody Blocks ART1-induced Mono-ADP-ribosylation and Improves Sensitivity to Osimertinib



Fawzi Abu Rous, MD
Hematology/Oncology Fellow
Henry Ford Health
Detroit, Michigan

Concomitant EGFR Exon 19 Deletion and ERBB2 Mutation in a Patient with Metastatic Non-small-cell Lung Cancer



Wonderful meeting—thanks for the opportunity... Having residents, fellows, and junior faculty as the focus made it much less intimidating.



Incredible networking experience to meet and collaborate with new colleagues.



New Young Investigators



Eric K. Singhi, MD
Assistant Professor
University of Texas, MD Anderson
Cancer Center
Houston, Texas

***Bridging the Communication Gap:
Development of Plain-language
Summaries of Pivotal Clinical Trials
for Patients with Lung Cancer***




Chetan Vakkalagadda, MD
Hematology/Oncology Fellow
Northwestern University
Chicago, Illinois

***A Randomized Phase II Clinical
Trial of Osimertinib with or without
Olaparib in Patients with Stage IV
EGFR-mutant NSCLC and Germline
Mutations in the Homologous
Recombination Repair Pathway***



Paul Stockhammer, MD, PhD
Resident Physician
Yale School of Medicine
New Haven, Connecticut

***Co-occurring Alterations in Multiple
Tumor Suppressor Genes Associate
with Outcomes in Patients with
EGFR-mutant Lung Cancer***



“

I have met colleagues/
friends who I hope to be
able to collaborate with
on future projects.

Returning Alumni



Christine Bestvina, MD (2019)
Assistant Professor
University of Chicago
Chicago, Illinois



Julia Rotow, MD (2020)
Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts



Fernando de Miguel, PhD (2020)
Senior Scientist
Tyra Biosciences
San Diego, California



Joshua Sabari, MD (2019)
Assistant Professor of Medicine
NYU Langone Health, Perlmutter Cancer Center
New York, New York



Catherine Meador, MD, PhD (2020)
Instructor in Medicine
Massachusetts General Hospital
Boston, Massachusetts



Elaine Shum, MD (2021)
Assistant Professor
NYU Langone Health, Perlmutter Cancer Center
New York, New York




Joseph Minhow Chan, MD, PhD (2020)
Instructor
Memorial Sloan Kettering Cancer Center
New York, New York



Nichole Yun, MD (2021)
Hematology/Oncology Fellow
Rush University Medical Center
Chicago, Illinois



Joshua Reuss, MD (2021)
Assistant Professor of Medicine
Georgetown Lombardi Comprehensive Cancer Center
Washington, DC






17 Institutions Represented

- Albert Einstein College of Medicine | New York, New York
- Dana-Farber Cancer Institute | Boston, Massachusetts
- Georgetown University Hospital, Lombardi Comprehensive Cancer Center | Washington, DC
- Harvard Medical School | Boston, Massachusetts
- Henry Ford Health | Detroit, Michigan
- Massachusetts General Hospital | Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center | New York, New York
- Northwestern University Medical Center | Chicago, Illinois
- NYU Langone Health, Perlmutter Cancer Center | New York, New York
- Rush University Medical Center | Chicago, Illinois
- Tisch Cancer Institute, Mount Sinai | New York, New York
- Tyra Biosciences | San Diego, California
- University of Chicago | Chicago, Illinois
- University of Texas, MD Anderson Cancer Center | Houston, Texas
- Vanderbilt University Medical Center | Nashville, Tennessee
- Wayne State University | Detroit, Michigan
- Yale School of Medicine | New Haven, Connecticut


PARTICIPANT GENDER



PARTICIPANT CATEGORY



PARTICIPANT DIVERSITY






What Participants Value Most



Incredible meeting. Learned so much and **loved interacting with great colleagues and friends.**



Patient advocate perspective. A group of focused individuals with one driving mission—understanding EGFR-mutant NSCLC and the development of more effective therapies for our patients.



Mentoring Moments and Small-group Networking Sessions



Mentoring moments and some small-group sessions offered **sage advice on topics I have little experience with or need guidance navigating.** Real-time feedback for both the presenter and observer was helpful for overall improvement in developing a presentational voice/style.

How Attending the Summit Will Impact Young Investigators' Careers



I'm starting to build a network of likeminded colleagues—both physicians and advocates alike—to allow for further collaboration. Participation in the summit also provided me with more confidence to pursue an academic path.



One of the best conferences I've ever attended. It will have a **long-lasting impact on my career** due to the mentorship that we received as well as the friendships/collaborations that we created.



Formative meeting for me early on in my career, gave me access to thought leaders and experts in the EGFR space, opened my mind to collaboration/opportunities, clinical trials for my patients, and helped build a community.





Publications

Marks JA, Wilgucki M, Liu SV, Reuss JE. Antibody-drug conjugates in non–small-cell lung cancer: emergence of a novel therapeutic class. *Curr Oncol Rep.* 2022;24(12):1829–1841.

Lee M, **Abu Rous F**, Borczuk A, et al. *Targeting Oncogenic Driver Mutations in Lung Cancer*. New York, New York: Cambridge University Press, 2023.

Abu Rous F, **Singhi EK**, Sridhar A, et al. Lung cancer treatment advances in 2022. *Cancer Invest.* 2023;41(1):12–24.

Safa H, **Abu Rous F**, Belani N, et al. Emerging biomarkers in immune oncology to guide lung cancer management. *Target Oncol.* 2023;18(1):25–49.

Singhi EK, Feldman J, West HJ. The Multidisciplinary Cancer Conference. *JAMA Oncol.* December 22, 2022. [Epub ahead of print.]

Honors and Awards

Fawzi Abu Rous, MD

2022 Doreen J. Putrah Cancer Research Foundation Scholar-in-Training Award, AACR

Eric Singhi, MD

2022 MD Anderson Awesome Job Award, MD Anderson Cancer Center

Paul Stockhammer, MD, PhD

2022 Education Award, International Association for the Study of Lung Cancer

Presentations

2022 International Association for the Study of Lung Cancer (IASCL) World Conference on Lung Cancer

August 6–9, 2022; Vienna, Austria

Stockhammer P, Grant M, Wurtz A, et al. Tumor suppressor gene alterations identified at disease progression impact outcomes in patients with EGFR-mutant lung cancer. Abstract EP08.02-125.

Vakkalagadda C, Bucheit L, Sun Z, et al. Germline HRR mutations in metastatic NSCLC and impact on progression-free survival: a single-center retrospective study. Abstract EP08.02-028.


Vakkalagadda C, Dressler D, Sun Z, et al. Impact of precision medicine methods on first-line therapies in metastatic non–small-cell lung cancer. Abstract EP04.01-007.

2023 IASLC Targeted Therapies of Lung Cancer Meeting

February 22–25, 2023; Santa Monica, California

Stockhammer P, Grant M, Wurtz A, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. Poster P07.





**MARK YOUR CALENDARS FOR THE 5TH ANNUAL
EGFR RESISTERS RESEARCH SUMMIT**

November 2-4, 2023 • Chicago, Illinois

Call for Abstract coming soon on Twitter



Follow us on Twitter

@EGFRSummit